Levofloxacin for the treatment of respiratory tract infections (Q38010784)

26 August 2017

Levofloxacin for the treatment of respiratory tract infections (English)

1 reference

26 August 2017

1 reference

Antoni Torres

1

1 reference

PubMed ID

22594848

26 August 2017

Adamantia Liapikou

series ordinal

2

1 reference

PubMed ID

22594848

26 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

8

1 reference

26 August 2017

1203-1212

1 reference

Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Guidelines for the management of adult lower respiratory tract infections--full version

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Bactericidal activity of levofloxacin against Mycoplasma pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Role of gemifloxacin in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Maintaining fluoroquinolone class efficacy: review of influencing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Acute exacerbation of chronic bronchitis: expanding short-course therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoni

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY An

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Defining, treating and preventing hospital acquired pneumonia: European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.688952

10.1517/14656566.2012.688952

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22594848